The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1139
September 16, 2002
View Complete Issue         Table of Contents 2019 
Tegaserod Maleate (Zelnorm) for IBS with Constipation
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Tegaserod Maleate (Zelnorm) for IBS with Constipation
September 16, 2002 (Issue: 1139)
Tegaserod maleate (teg a ser' od; Zelnorm - Novartis), a serotonin derivative, has received FDA approval for short-term treatment of women with irritable bowel syndrome (IBS) whose primary symptom is constipation. Alosetron (Lotronex), which was...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Tegaserod Maleate (Zelnorm) for IBS with Constipation
Article code: 1139a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.